[go: up one dir, main page]

MA32902B1 - Derives d'arylcyclopropylacetamide utiles comme activateurs de la glucokinase - Google Patents

Derives d'arylcyclopropylacetamide utiles comme activateurs de la glucokinase

Info

Publication number
MA32902B1
MA32902B1 MA33945A MA33945A MA32902B1 MA 32902 B1 MA32902 B1 MA 32902B1 MA 33945 A MA33945 A MA 33945A MA 33945 A MA33945 A MA 33945A MA 32902 B1 MA32902 B1 MA 32902B1
Authority
MA
Morocco
Prior art keywords
arilcyclopropylacetamide
glucokinase
activation
derivatives
useful
Prior art date
Application number
MA33945A
Other languages
Arabic (ar)
English (en)
Inventor
Melendo Ana Belen Bueno
Francisco Javier Agejas-Chicharro
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA32902B1 publication Critical patent/MA32902B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur un composé de formule (A) et sur des compositions pharmaceutiques pour le traitement du diabète.
MA33945A 2008-12-19 2011-06-14 Derives d'arylcyclopropylacetamide utiles comme activateurs de la glucokinase MA32902B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19
PCT/US2009/067603 WO2010080333A1 (fr) 2008-12-19 2009-12-11 Dérivés d'arylcyclopropylacétamide utiles en tant qu'activateurs de glucokinase

Publications (1)

Publication Number Publication Date
MA32902B1 true MA32902B1 (fr) 2011-12-01

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33945A MA32902B1 (fr) 2008-12-19 2011-06-14 Derives d'arylcyclopropylacetamide utiles comme activateurs de la glucokinase

Country Status (34)

Country Link
US (1) US8063079B2 (fr)
EP (1) EP2379517B1 (fr)
JP (1) JP5497064B2 (fr)
KR (1) KR101290437B1 (fr)
CN (1) CN102256952B (fr)
AR (1) AR074470A1 (fr)
AU (1) AU2009335931B2 (fr)
BR (1) BRPI0923183B1 (fr)
CA (1) CA2746746C (fr)
CO (1) CO6382120A2 (fr)
CR (1) CR20110342A (fr)
DK (1) DK2379517T3 (fr)
DO (1) DOP2011000197A (fr)
EA (1) EA019055B1 (fr)
EC (1) ECSP11011150A (fr)
ES (1) ES2435242T3 (fr)
HR (1) HRP20130983T1 (fr)
IL (1) IL213210A (fr)
JO (1) JO2979B1 (fr)
MA (1) MA32902B1 (fr)
MX (1) MX2011006434A (fr)
MY (1) MY180567A (fr)
NZ (1) NZ592930A (fr)
PA (1) PA8851901A1 (fr)
PE (1) PE20120339A1 (fr)
PL (1) PL2379517T3 (fr)
PT (1) PT2379517E (fr)
SG (1) SG172256A1 (fr)
SI (1) SI2379517T1 (fr)
TN (1) TN2011000294A1 (fr)
TW (1) TWI395748B (fr)
UA (1) UA104742C2 (fr)
WO (1) WO2010080333A1 (fr)
ZA (1) ZA201103944B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
JP6086566B2 (ja) * 2013-11-22 2017-03-01 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1282612E (pt) 2000-05-03 2005-04-29 Hoffmann La Roche Actividades heteroaromaticas da glucoquinase a vase de alcinilo-fenilo
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
EP1283830B1 (fr) 2000-05-08 2008-06-18 F. Hoffmann-La Roche Ag Activateurs de glucokinase de type phenylamides substitues para-amine
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (fr) 2003-02-11 2004-08-26 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
JP4432901B2 (ja) * 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
US20080242869A1 (en) 2004-04-21 2008-10-02 Matthew Fyfe Tri(Cyclo) Substituted Amide Compounds
WO2006016194A1 (fr) 2004-08-12 2006-02-16 Prosidion Limited Phénylacétamides substitués et leur utilisation en tant qu’activateurs de la glucokinase
KR101066882B1 (ko) * 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
AU2006265653A1 (en) * 2005-07-01 2007-01-11 Novartis Ag Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
US7514439B2 (en) 2005-07-11 2009-04-07 Mitsubishi Tanabe Pharma Corporation Oxime derivative and preparations thereof
EP1915367A1 (fr) * 2005-08-09 2008-04-30 AstraZeneca AB Dérivés hétéroarylcarbamoylbenzène pour traiter le diabète
CA2626475A1 (fr) 2005-11-03 2007-05-10 Prosidion Limited Amides a substitution tricyclo
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
WO2007051846A1 (fr) 2005-11-03 2007-05-10 Prosidion Ltd Amides a substitution tricyclo
WO2008012227A2 (fr) * 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles comme activateurs de glucokinase
EP2105435A4 (fr) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Dérivé d'hydrazone
NZ588462A (en) 2008-04-28 2012-07-27 Kyorin Seiyaku Kk Cyclopentylacrylic acid amide derivative

Also Published As

Publication number Publication date
TW201029999A (en) 2010-08-16
CA2746746A1 (fr) 2010-07-15
AU2009335931A1 (en) 2011-07-07
EP2379517B1 (fr) 2013-08-28
WO2010080333A1 (fr) 2010-07-15
AU2009335931B2 (en) 2012-05-31
PE20120339A1 (es) 2012-04-16
CN102256952B (zh) 2013-12-11
EP2379517A1 (fr) 2011-10-26
CN102256952A (zh) 2011-11-23
SI2379517T1 (sl) 2013-10-30
SG172256A1 (en) 2011-07-28
CA2746746C (fr) 2013-09-24
CR20110342A (es) 2011-09-14
DK2379517T3 (da) 2013-09-30
KR20110086751A (ko) 2011-07-29
EA019055B1 (ru) 2013-12-30
US8063079B2 (en) 2011-11-22
JP2012512874A (ja) 2012-06-07
BRPI0923183A8 (pt) 2017-09-12
CO6382120A2 (es) 2012-02-15
EA201170845A1 (ru) 2011-12-30
ECSP11011150A (es) 2011-07-29
HRP20130983T1 (hr) 2013-11-22
UA104742C2 (uk) 2014-03-11
NZ592930A (en) 2013-01-25
ZA201103944B (en) 2012-11-28
US20100160395A1 (en) 2010-06-24
KR101290437B1 (ko) 2013-07-29
JO2979B1 (en) 2016-03-15
BRPI0923183A2 (pt) 2016-02-16
IL213210A (en) 2015-03-31
TWI395748B (zh) 2013-05-11
MX2011006434A (es) 2011-07-19
JP5497064B2 (ja) 2014-05-21
PT2379517E (pt) 2013-11-21
ES2435242T3 (es) 2013-12-17
PA8851901A1 (es) 2010-07-27
MY180567A (en) 2020-12-02
PL2379517T3 (pl) 2014-01-31
DOP2011000197A (es) 2011-09-15
TN2011000294A1 (en) 2012-12-17
BRPI0923183B1 (pt) 2019-03-19
AR074470A1 (es) 2011-01-19
IL213210A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
MA32904B1 (fr) Composes de purine
MA33428B1 (fr) Agonistes du gpr119
MA32171B1 (fr) Compose heterocyclique
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
DK2150530T3 (da) Substituerede sulfonamid-derivater
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
EA200970401A1 (ru) 2-[1-ФЕНИЛ-5-ГИДРОКСИ ИЛИ МЕТОКСИ-4-АЛЬФА-МЕТИЛГЕКСАГИДРОЦИКЛОПЕНТА[f]ИНДАЗОЛ-5-ИЛ] ЭТИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ЛИГАНДОВ ГЛЮКОКОРТИКОИДНОГО РЕЦЕПТОРА
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
TW200736247A (en) Compounds for the treatment of inflammatory disorders
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
DE602007008524D1 (de) Spiroimidazol-derivate als ppar-modulatoren
GEP20146125B (en) Aminopyrimidines as syk inhibitors
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
EP2450046A4 (fr) Composition à visée médicale pour le traitement de la bronchite et sa préparation
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EP2051967A4 (fr) Dérivés de benzimidazole utilisables pour le traitement des troubles liés au récepteur des vallinoïdes trpv1
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique